less side effects semaglutide or tirzepatide Anti-obesity Medications and Menopausal Hormone Therapy Taking the anti-obesity medication and menopausal hormone therapy at the same time can fuel additional weight loss in postmenopausal women who have obesity overweight Semaglutide vs. Tirzepatide: Which Weight

This analysis only focused on switching patterns and did not look into patients who discontinued their GLP-1 RA in association with this change

By supporting weight loss and healthier lifestyle habits, semaglutide can also help lower the risk of heart disease, stroke, and certain cancers

Nasal health Severe congestion, allergic rhinitis, or acute upper respiratory infections can reduce absorption

Key mechanistic features: Pulsatile GH release: Maintains natural GH secretion patterns rather than constant elevation Feedback preservation: Does not override normal hypothalamic-pituitary feedback loops IGF-1 elevation: Secondary increase in insulin-like growth factor-1 (IGF-1) through hepatic stimulation Lipolytic effects: Documented reduction in visceral adipose tissue (VAT) in clinical trials Tesamorelin FDA Approval History The Egrifta FDA approval timeline represents one of the few success stories for peptide therapeutics reaching market authorization

This focused approach, while providing insights into comparisons between tirzepatide and semaglutide, is not as well suited for an evaluation of the two medications vs the common comparators included in the analysis